News World Center

Immune Thrombocytopenia (ITP) Market Worth Around 2361.2 Million USD by 2023 | Blooming CAGR 5.78% In International Market

Press release   •   Apr 16, 2019 01:54 EDT

Global Immune Thrombocytopenia (ITP) Market is projected to grow at blooming CAGR of around 5.78% over the forecast period and market size will reach worth around 2361.2 Million US$ in 2018-2023.

The new research from Ameco Research on Global Immune Thrombocytopenia (ITP) Market Report for 2023 intends to offer target audience with the fresh outlook on market and fill in the knowledge gaps with the help of processed information and opinions from industry experts. The information in the research report is well-processed and a report is accumulated by industry professionals and seasoned experts in the field to ensure of the quality of research.

The research is backed by extensive and in-depth secondary research which involves reference to various statistical databases, national government documents, relevant patent and regulatory databases, news articles, press releases, company annual reports, webcasts, financial reports, and a number of internal and external proprietary databases. This estimated data is cross-checked with industry experts from various leading companies in the market. After the entire authentication process, these reports are shared with subject matter experts (SMEs) for adding further value and to gain their insightful opinion on the research. With such robust process of data extraction, verification, and finalization, we firmly endorse the quality of our research. With such extensive and in-depth research and comprehensive coverage of information, it is always a possibility of clients finding their desired information in the report with enclosure of key components and valuable statistics in all regards.

Download Sample Copy Of This Report From Here:


Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by improper clotting of blood. ITP can cause excessive bruising and bleeding owing to the unusually low levels of platelets or thrombocytes in the blood. ITP can occur in both children and adults. ITP can be classified as primary, i.e., occurring on its own, or secondary, occurring alongside another condition. Autoimmune diseases, chronic infections, medications, pregnancy, and certain cancers are common secondary triggers of ITP. The increasing prevalence of ITP is expected to contribute to the growth of the market over the forecast period.

The global immune thrombocytopenia (ITP) market has been segmented, by type, treatment, and end user.

Based on type, the global immune thrombocytopenia (ITP) market has been categorized as acute immune thrombocytopenia and chronic immune thrombocytopenia.

On the basis of treatment, the global immune thrombocytopenia (ITP) market is further sub-segmented into corticosteroids, thrombopoietin receptor agonists, and intravenous immunoglobulins (IVIG).

Based on end user, the market has been classified as hospitals and clinics, specialty centers, and research and academic institutes.

The global immune thrombocytopenia (ITP) market was valued at USD 1,670.9 million in 2017 and is expected to register a CAGR of 5.78% during the forecast period from 2018 to 2023.

Key Players

Some of the key players in the global immune thrombocytopenia (ITP) market are Amgen Inc., CSL Limited, Dova Pharmaceuticals, Jiangsu Hengrui Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd, Ligand Pharmaceuticals, Inc, Novartis AG, Rigel Pharmaceuticals, Inc, Shire, and Shionogi Inc.

View Detail Report With Complete Table of Content@

Objectives of the Study

  • To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global immune thrombocytopenia (ITP) market
    • To provide insights into factors influencing and affecting market growth
    • To provide historical and forecast revenue of market segments and sub-segments with respect to countries
    • To provide strategic profiling of key players in the market and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
    • To provide economic factors that influence the global immune thrombocytopenia (ITP) market
    • To provide a detailed analysis of the value chain and supply chain of the global immune thrombocytopenia (ITP) market
  • Target Audience

    • Research and Development (R&D) Companies
    • Academic Institutes and Universities
    • Pharmaceutical Companies
    • Raw Material Suppliers
    • Suppliers and Distributors
    • Government
    • Potential Investors

    Key Findings

    • The global immune thrombocytopenia (ITP) market is expected to reach USD 2,361.2 million by 2023 at a CAGR of 5.78% from 2018 to 2023
    • Based on type, the chronic immune thrombocytopenia segment holds the largest market share and is expected to reach USD 2,036.9 million by 2023 at a CAGR of 5.94% from 2018 to 2023
    • The market in the Americas is expected to account for the largest share of the global immune thrombocytopenia (ITP) market and is projected to reach USD 1,069.8 million by 2023
    • The immune thrombocytopenia (ITP) market in Asia-Pacific is projected to be the fastest-growing at a CAGR of 4.40% from 2018 to 2023

    Regional Analysis

  • Americas
    o North America
     US
     Canada
    o Latin America
  • Europe
    o Western Europe
     Germany
     France
     UK
     Italy
     Spain
     Rest of Western Europe
    o Eastern Europe
  • Asia-Pacific
    o Japan
    o China
    o India
    o Australia
    o South Korea
    o Rest of Asia-Pacific
  • Middle East & Africa
    o Middle East
    o Africa
  • Available customization:

    With the given market information, Ameco research offers customization's in line with the company's specific wishes. The following customization choices unit of measurement accessible for the report:
    Regional and country-level analysis of the Global Immune Thrombocytopenia (ITP) Market, by end-use.
    Detailed analysis and profiles of additional market players.

    Table of Contents

    Global Immune Thrombocytopenia (ITP) Market Research Report Forecast to 2023

    1 Report Prologue

    2 Executive Summary

    3 Introduction
    3.1 Definition
    3.2 Scope of the Study
    3.3 List of Assumptions
    3.4 Market Structure

    4 Research Methodology
    4.1 Research Process
    4.2 Primary Research
    4.3 Secondary Research
    4.4 Market Size Estimation
    4.5 Forecast Model

    5 Market Dynamics
    5.1 Overview
    5.2 Drivers
    5.2.1 Rising prevalence of Immune Thrombocytopenia (ITP)
    5.2.2 Growing financial support by various private and government organizations
    5.3 Restraints
    5.3.1 Side effects of treatment options
    5.3.2 High cost of IVIG treatment
    5.4 Opportunities
    5.4.1 Emerging therapies in immune thrombocytopenia

    6 Market Factor Analysis
    6.1 Value chain analysis
    6.1.1 R&D and Designing
    6.1.2 Manufacturing
    6.1.3 Distribution & Sales
    6.1.4 Post-Sales Monitoring
    6.2 Porter’s Five Forces Model
    6.2.1 Bargaining Power of Suppliers
    6.2.2 Bargaining Power of Buyers
    6.2.3 Threat of New Entrants
    6.2.4 Threat of Substitutes
    6.2.5 Intense Rivalry

    7 Global Immune Thrombocytopenia (ITP) Market by Type
    7.1 Overview
    7.2 Acute Immune Thrombocytopenia
    7.3 Chronic Immune Thrombocytopenia

    8 Global Immune Thrombocytopenia (ITP) Market by Treatment
    8.1 Overview
    8.2 Corticosteroids
    8.3 Thrombopoietin receptor agonists
    8.4 Intravenous Immunoglobulins (IVIG)

    9 Global Immune Thrombocytopenia (ITP) Market by End-user
    9.1 Overview
    9.2 Hospital & Clinics
    9.3 Specialty Centers
    9.4 Research and Academic Institutes

    10 Global Immune Thrombocytopenia (ITP) Market by Region
    10.1 Overview
    10.2 Americas
    10.2.1 North America US Canada
    10.2.2 South America
    10.3 Europe
    10.3.1 Western Europe Germany France UK Italy Spain Rest of Western Europe
    10.3.2 Eastern Europe
    10.4 Asia-Pacific
    10.4.1 Japan
    10.4.2 China
    10.4.3 India
    10.4.4 South Korea
    10.4.5 Australia
    10.4.6 Rest of Asia-Pacific
    10.5 Middle East & Africa
    10.5.1 Middle East
    10.5.2 Africa

    11 Competitive Landscape
    11.1 Overview
    11.2 Company Share Analysis

    12 Company Profiles
    12.1 Amgen Inc.
    12.1.1 Company Overview
    12.1.2 Financial Overview
    12.1.3 Products/Services Offered
    12.1.4 Key Developments
    12.1.5 SWOT Analysis
    12.1.6 Key Strategy
    12.2 CSL Limited
    12.2.1 Financial Overview
    12.2.2 Products/Services Offered
    12.2.3 Key Developments
    12.2.4 SWOT Analysis
    12.2.5 Key Strategy
    12.3 Dova Pharmaceuticals
    12.3.1 Company Overview
    12.3.2 Financial Overview
    12.3.3 Products/Services Offered
    12.3.4 Key Developments
    12.3.5 SWOT Analysis
    12.3.6 Key Strategy
    12.4 F. Hoffmann-La Roche Ltd
    12.4.1 Company Overview
    12.4.2 Financial Overview
    12.4.3 Products/Services Offered
    12.4.4 Key Developments
    12.4.5 SWOT Analysis
    12.4.6 Key Strategy
    12.5 Jiangsu Hengrui Pharmaceutical Co., Ltd.
    12.5.1 Company Overview
    12.5.2 Financial Overview
    12.5.3 Products/Services Offered
    12.5.4 SWOT Analysis
    12.5.5 Key Developments
    12.5.6 Key strategy
    12.6 Kyowa Hakko Kirin Co., Ltd.
    12.6.1 Company Overview
    12.6.2 Financial Overview
    12.6.3 Products/Services Offered
    12.6.4 Key Developments
    12.6.5 SWOT Analysis
    12.6.6 Key Strategy
    12.7 Ligand Pharmaceuticals, Inc.
    12.7.1 Company Overview
    12.7.2 Financial Overview
    12.7.3 Products/Services Offered
    12.7.4 Key Developments
    12.7.5 SWOT Analysis
    12.7.6 Key Strategy
    12.8 Novartis AG
    12.8.1 Company Overview
    12.8.2 Financial Overview
    12.8.3 Products/Services Offered
    12.8.4 Key Developments
    12.8.5 SWOT Analysis
    12.8.6 Key Strategy
    12.9 Rigel Pharmaceuticals, Inc.
    12.9.1 Company Overview
    12.9.2 Financial Overview
    12.9.3 Products/Services Offered
    12.9.4 Key Developments
    12.9.5 SWOT Analysis
    12.9.6 Key Strategy
    12.1 Shire
    12.10.1 Company Overview
    12.10.2 Financial Overview
    12.10.3 Products/Services Offered
    12.10.4 Key Developments
    12.10.5 SWOT Analysis
    12.10.6 Key Strategy
    12.11 Shionogi Inc.
    12.11.1 Company Overview
    12.11.2 Financial Overview
    12.11.3 Products/Services Offered
    12.11.4 Key Developments
    12.11.5 SWOT Analysis
    12.11.6 Key Strategy

    13 Appendix
    13.1 Discussion Blue Print

    Quick Buy This Premium Report From Here:

    About Us:

    Ameco Research is the one spot destination for all your research needs. Ameco Research holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.

    Email:| Call: + 1 407 915 4157

    Browse More For Latest Update :

    Ameco Research